AI
June 2025
To determine the prevalence and incidence of Dyslexia among individuals in a defined population. This objective outlines the primary aim of the study, which is to establish the frequency of Dyslexia within a specific age group and geographic area, while also seeking to understand potential factors contributing to its development. Adjustments can be made based on the study's scope, available data, and specific research questions of interest.
Dyslexia Study USP:
This epidemiological study on Dyslexia stands out due to its comprehensive approach in establishing precise prevalence rates, identifying novel risk factors, and exploring geographical variations in a diverse population.
By integrating advanced imaging techniques with robust statistical analyses, the study aims to provide actionable insights to identify treatment opportunities, target population, and an overview on public health initiatives aimed at mitigating the impact of Dyslexia related health problems.
Through meticulous data collection and rigorous methodology, the study not only contributes to the scientific understanding of Dyslexia but also serves as a foundation for future research events and healthcare policymaking in addressing this increasing Dyslexia cases.
Dyslexia related Study Overview:
The study Defines Dyslexia as an advanced form of disease. The significance of studying Dyslexia epidemiology is due to its increasing prevalence in different age populations.
Dyslexia Study Design:
Population: The target population and the sampling method (e.g., random sampling from healthcare registries or population databases)
Data Collection: Detail methods for identifying Dyslexia cases (e.g., clinical examination, imaging studies) and demographic data (age, sex, ethnicity).
Dyslexia Epidemiological Parameters:
Prevalence: Prevalence rates considered per 1,000 or 10,000 population.
Incidence: Determine annual incidence rates per 1,000 person-years.
Risk Factors: Analyse associations between obesity and potential risk factors (e.g., age, smoking, genetics).
Geographical Variations: Compare prevalence or incidence rates across different regions or countries.
Dyslexia study summary:
Dyslexia study summarizes the prevalence, incidence, possible risk factors, and geographic variations of the Dyslexia worldwide.
Dyslexia Disease overview:
Dyslexia is a neurobiological learning disability, affecting many individuals in world, causing problems to patients in processing language, challenges to read, write and spell accurately, making it one of the major health problems.
Dyslexia based on the cause is segmented into developmental and acquired types.
Developmental dyslexia is present in patients from birth and includes primary and secondary dyslexia. Primary dyslexia is caused due to inherited genes or genetic mutations. It is observed that 40 to 60% children get dyslexia whose parents are suffering from it. In primary type dysfunction is found to be on left side of the brain, involved in reading, which affects persons language processing ability. Issues in neurological development during the foetal period (in the womb) causes Secondary dyslexia, symptoms are seen in early childhood. Acquired dyslexia is caused due to in injury or illness in childhood or adulthood which can be brain trauma or stroke or dementia, also known as trauma dyslexia or alexia.
There are many service-based treatment option for dyslexia treatment, it may involve, time spent with speech and language therapist, tutors, special education teachers, early intervention will give importance to vocabulary, comprehension, necessary skills like phonics. As students start taking education intervention will try to improve word meaning understanding, improved comprehension, more challenging reading and other strategies to excel.
Strategies to help them to overcome their health challenges include use of taping lectures instead of writing notes, listening to books on tape rather than reading them, using flash cards checking spelling and grammar using computer software.
Other supporting Treatment medications used for dyslexia are Antihistamines, Central Nervous Stimulant, Anti-Myoclonic, Attention-Deficit Hyperactivity Disorder (ADHD), Drug. Several key market players for dyslexia include Pfizer, Inc. (US), Speechify Inc. (US), Jubilant Pharma Limited (Singapore), Lingit AS (Norway), Soli (UK), Novartis AG (Switzerland), Lyfta (UK), GlaxoSmithKline (UK), Teva Pharmaceutical Industries Ltd (Israel), Eli Lilly & Company (US), RPG Life Sciences Ltd (India), Hopalai D.O.O. (Slovenia).
Every one out of ten people are found to be affected by dyslexia, out of global population of 7.8 billion people, 780 million people have dyslexia across the world. 5 to 15 % of Americans with 14.5 to 43.5 million children and adults are seen to be dyslexic. Approximately 1 out of 5 students in U.S, that is about 15 to 20% of population is suffering with language-based learning disabilities such as dyslexia.
Dyslexia Demographic and Environmental Risk Factors:
Age and sex: Dyslexia prevalence is found to be seen in higher rate in boys than girls, with nearly 2:1 ratio compared to girls having low prevalence rates. According to a 2024 research study published in NCBI percentage of dyslexia in 3rd grade boys and girls was 71.4% and 28.6%. Similarly, the percentages were 80.4% and 19.6%, 71.9% and 28.1%, and 75% and 25% in the 4th, 5th, and 6th grades respectively. The prevalence was seen to be highest in males, about 80% and lowest in females about 20%.
Risk Factors causing Dyslexia: Genetics has major role to play in dyslexia cause. Research shows that dyslexia can run in families can run in families due to the hereditary component, close family member suffering with dyslexia like parent or sibling, increases chances of other members of family getting affected with dyslexia as well. Premature birth, low weight, prenatal and perinatal complications can contribute to development of delays and disruptions in brain development, which can increase chances of dyslexia in these individuals. Acquired dyslexia can be caused to individuals due to illness and injury like stroke, brain trauma, dementia.
Dyslexia Market Scope:
Drivers: A large population suffering from learning disabilities prone to developing dyslexia is adding up several patients with dyslexia. Additionally, an increasing number of learning programs focused on dyslexia is helping the growth of the dyslexia treatment & diagnosis market. For example, non-profit organizations such as The African Dyslexia Organization is raising donations for “Free dyslexia diagnosis children fund” and increasing awareness about dyslexia in the region. An increase in the level of awareness in developing regions about dyslexia is expected to increase the diagnosis rate during the forecast period.
Restraints: Lack of awareness about this disability condition, symptoms, treatments. Other challenge is delay in diagnosis the disability are the major factors related to dyslexia which hampers the growth of dyslexia market.
Market Introduction
Market Scope
LIST OF TABLES
TABLE 1: GLOBAL NUMBER OF PATIENTS FOR DYSLEXIA FROM 2019-2032
TABLE 2: GLOBAL PREVALENCE RATE FOR DYSLEXIA FROM 2019-2023
TABLE 3: GLOBAL INCIDENCE RATE FOR DYSLEXIA FROM 2019-2023
TABLE 4: NORTH AMERICA NUMBER OF PATIENTS DYSLEXIA FROM 2019-2032
TABLE 5: NORTH AMERICA PREVALENCE RATE FOR DYSLEXIA FROM 2019-2023
TABLE 6: NORTH AMERICA INCIDENCE RATE FOR DYSLEXIA FROM 2019-2023
TABLE 7: EUROPE NUMBER OF PATIENTS FOR DYSLEXIA FROM 2019-2032
TABLE 8: EUROPE PREVALENCE RATE FOR DYSLEXIA FROM 2019-2023
TABLE 9: EUROPE INCIDENCE RATE FOR DYSLEXIA FROM 2019-2023
TABLE 10: AISA-PACIFIC NUMBER OF PATIENTS FOR DYSLEXIA FROM 2019-2032
TABLE 11: AISA-PACIFIC PREVALENCE RATE FOR DYSLEXIA FROM 2019-2023
TABLE 12: AISA-PACIFIC INCIDENCE RATE FOR DYSLEXIA FROM 2019-2023
TABLE 13: ROW NUMBER OF PATIENTS FOR DYSLEXIA FROM 2019-2032
TABLE 14: ROW PREVALENCE RATE FOR DYSLEXIA FROM 2019-2023
TABLE 15: ROW INCIDENCE RATE FOR DYSLEXIA FROM 2019-2023
LIST OF FIGURES
FIG 1: GLOBAL NUMBER OF PATIENTS FOR DYSLEXIA FROM 2019-2032
FIG 2: GLOBAL PREVALENCE RATE FOR DYSLEXIA FROM 2019-2023
FIG 3: GLOBAL INCIDENCE RATE FOR DYSLEXIA FROM 2019-2023
FIG 4: NORTH AMERICA NUMBER OF PATIENTS FOR DYSLEXIA FROM 2019-2032
FIG 5: NORTH AMERICA PREVALENCE RATE FOR DYSLEXIA FROM 2019-2023
FIG 6: NORTH AMERICA INCIDENCE RATE FOR DYSLEXIA FROM 2019-2023
FIG 7: EUROPE NUMBER OF PATIENTS FOR DYSLEXIA ROM 2019-2032
FIG 8: EUROPE PREVALENCE RATE FOR DYSLEXIA FROM 2019-2023
FIG 9: EUROPE INCIDENCE RATE FOR DYSLEXIA FROM 2019-2023
FIG 10: AISA-PACIFIC NUMBER OF PATIENTS FOR DYSLEXIA FROM 2019-2032
FIG 11: AISA-PACIFIC PREVALENCE RATE FOR DYSLEXIA FROM 2019-2023
FIG 12: AISA-PACIFIC INCIDENCE RATE FOR DYSLEXIA FROM 2019-2023
FIG 13: ROW NUMBER OF PATIENTS FOR DYSLEXIA FROM 2019-2032
FIG 14: ROW PREVALENCE RATE FOR DYSLEXIA FROM 2019-2023
FIG 15: ROW INCIDENCE RATE FOR DYSLEXIA FROM 2019-2023
No reports available yet for Pricing Analysis. Select or create a report to view detailed overview.
Table of contents for Pricing Analysis will appear here once a report is selected.
No reports available yet for Brand Share Analysis. Select or create a report to view detailed overview.
Table of contents for Brand Share Analysis will appear here once a report is selected.
Overview for Regulatory Landscape (based on available reports).
mRNA Vaccines And Therapeutics Regulatory Landscape: Product Overview mRNA vaccines and therapeutics are class of medical treatments that utilize synthetic messenger RNA (mRNA) to instruct the body’s cells to produce specific proteins. In the case of vaccines, these proteins mimic parts of a virus or pathogen, making the immune system to recognize and respond to future infections. For therapeutics, the mRNA directs cells to produce Specific proteins, which help to treat or manage diseases. mRNA Vaccines And Therapeutics Applications: mRNA vaccines offer rapid development and broad protection against various infectious diseases such as influenza, RSV, Zika, rabies, Ebola, and COVID-19 variants. They also support innovative delivery systems that enhance mucosal immunity, making them effective tool in modern disease prevention. One of the most promising uses of mRNA technology is in oncology. Personalized cancer vaccines are being developed to encode tumor-specific antigens, enabling the immune system to recognize and attack cancer cells. mRNA is showing promise in treating rare inherited diseases such as methylmalonic acidemia and glycogen storage disorders. These conditions often lack effective treatments, and mRNA offers a less invasive and more adaptable alternative to traditional gene therapy. Researchers are investigating how mRNA can be used to modulate immune responses in autoimmune diseases like multiple sclerosis and rheumatoid arthritis. By fine-tuning immune activity, mRNA could help reduce inflammation and prevent immune attacks on healthy tissue. mRNA Vaccines And Therapeutics Product Development steps: Figure: overview of FDA mRNA Vaccines and Therapeutics Approval and Development Process mRNA Vaccines And Therapeutics Market Size Overview: mRNA Vaccines and Therapeutics Market Size was estimated at 6.06 (USD Billion) in 2023. The mRNA Vaccines and Therapeutics Market Industry is expected to grow from 7.23 (USD Billion) in 2024 to 50.0 (USD Billion) by 2035. The mRNA Vaccines and Therapeutics Market CAGR (growth rate) is expected to be around 19.22% during the forecast period (2025-2035). mRNA Vaccines And Therapeutics Regulatory Landscape: There are several key regulatory agencies who oversee the approval and monitoring of mRNA Vaccines And Therapeutics to ensure their safety, efficacy, and quality. Regulatory agencies Regulatory Ministry Federal Food and Drug Administration United States: Department of Health and Human Services (HHS) The Medicines and Healthcare products Regulatory Agency United Kingdom: The Medicines and Healthcare products Regulatory Agency (MHRA) under the Department of Health and Social Care (DHSC) Central Drug Standard Control Organization India: The Ministry of Health and Family Welfare South African Health Products Regulatory Authority (SAHPRA) National Department of Health. Pharmaceuticals and Medical Devices Agency (PMDA) Japan: Ministry of Health, Labour and Welfare. National Medical Products Administration (NMPA) China: The Ministry of Health Health Sciences Authority Singapore: The Ministry of Health European Medicine Agency European union Brazilian Health Regulatory Agency (Anvisa) Ministry of Health, part of the Brazilian National Health System (SUS) mRNA Vaccines And Therapeutics Guidelines: mRNA-based therapies are emerging as a transformative approach for treating a wide range of diseases that are resistant to conventional treatments, including infectious diseases, metabolic genetic disorders, cancer, cardiovascular, and cerebrovascular conditions. These therapies offer several advantages, such as high efficacy, minimal side effects, and ease of production. The success of mRNA vaccines during the COVID-19 pandemic, particularly BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna, demonstrated the potential of this technology. These vaccines showed approximately 90% effectiveness in preventing infection in fully vaccinated individuals and around 80% in those partially vaccinated. mRNA Vaccines And Therapeutics Classification of the Product: mRNA Vaccines And Therapeutics Regulatory Process Overview, By Country: mRNA products are classified as biologics by the U.S. Food and Drug Administration (FDA), The Center for Biologics Evaluation and Research (CBER) under Food and Drug Administration (FDA) is responsible for the regulation of all the biologics including mRNA vaccines and therapeutics and make sure ...No reports available yet for Clinical Trial Analysis. Select or create a report to view detailed overview.
Table of contents for Clinical Trial Analysis will appear here once a report is selected.
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”